Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.

Heightened caution, improved physician and patient communication, and equitable access are key priorities.

Device innovation has potential to improve patient outcomes over time, yet prospective benefits must be considered in light of risks.

Information different patients need or want about cybersecurity risk varies, so communicating clearly is always key.

If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.

Some clinicians offering image-guided procedures have little training in palliative medicine, which is both a clinical and an ethical problem.

Ari Ne’eman joins Ethics Talk to discuss his article, When Disability is Defined by Behavior, Outcome Measures Should Not promote “Passing”.

Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"

Dr Donna-Bea Tillman joins Ethics Talk to discuss her article: "What Should the Public Know About Implantable Material and Device Innovation in the US?"

Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"